Role of the Mycobacterium tuberculosis P55 Efflux Pump in Intrinsic Drug Resistance, Oxidative Stress Responses, and Growth
- 1 September 2009
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (9) , 3675-3682
- https://doi.org/10.1128/aac.00550-09
Abstract
Bacterial efflux pumps have traditionally been studied as low-level drug resistance determinants. Recent insights have suggested that efflux systems are often involved with fundamental cellular physiological processes, suggesting that drug extrusion may be a secondary function. In Mycobacterium tuberculosis, little is known about the physiological or drug resistance roles of efflux pumps. Using Mycobacterium bovis BCG as a model system, we showed that deletion of the Rv1410c gene encoding the P55 efflux pump made the strain more susceptible to a range of toxic compounds, including rifampin (rifampicin) and clofazimine, which are first- and second-line antituberculosis drugs. The efflux pump inhibitors carbonyl cyanide m-chlorophenylhydrazone (CCCP) and valinomycin inhibited the P55-determined drug resistance, suggesting the active export of the compounds by use of the transmembrane proton and electrochemical gradients as sources of energy. In addition, the P55 efflux pump mutant was more susceptible to redox compounds and displayed increased intracellular redox potential, suggesting an essential role of the efflux pump in detoxification processes coupled to oxidative balance within the cell. Finally, cells that lacked the p55 gene displayed smaller colony sizes and had a growth defect in liquid culture. This, together with an increased susceptibility to the cell wall-targeting compounds bacitracin and vancomycin, suggested that P55 is needed for proper cell wall assembly and normal growth in vitro. Thus, P55 plays a fundamental role in oxidative stress responses and in vitro cell growth, in addition to contributing to intrinsic antibiotic resistance. Inhibitors of the P55 efflux pump could help to improve current treatments for tuberculosis.Keywords
This publication has 40 references indexed in Scilit:
- Function of a Mycobacterial Major Facilitator Superfamily Pump Requires a Membrane-Associated LipoproteinJournal of Bacteriology, 2008
- Spread of Extensively Drug-resistant TuberculosisEmerging Infectious Diseases, 2007
- Contribution of the Rv2333c efflux pump (the Stp protein) from Mycobacterium tuberculosis to intrinsic antibiotic resistance in Mycobacterium bovis BCGJournal of Antimicrobial Chemotherapy, 2007
- LfrR Is a Repressor That Regulates Expression of the Efflux Pump LfrA in Mycobacterium smegmatisAntimicrobial Agents and Chemotherapy, 2006
- Multidrug-resistance efflux pumps ? not just for resistanceNature Reviews Microbiology, 2006
- Clinically Relevant Chromosomally Encoded Multidrug Resistance Efflux Pumps in BacteriaClinical Microbiology Reviews, 2006
- Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitumJournal of Antimicrobial Chemotherapy, 2006
- Role of mycobacterial efflux transporters in drug resistance: an unresolved questionFEMS Microbiology Reviews, 2006
- mmpL7 Gene of Mycobacterium tuberculosis Is Responsible for Isoniazid Efflux in Mycobacterium smegmatisAntimicrobial Agents and Chemotherapy, 2005
- Do physiological roles foster persistence of drug/multidrug-efflux transporters? A case studyNature Reviews Microbiology, 2005